- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 30.09. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Laidlaw stuft Aeon Biopharma mit "Buy" ein: Aktie mit erheblichem Kurspotenzial | 2 | Investing.com Deutsch | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 09.09. | Laidlaw initiates Aeon Biopharma stock coverage with buy rating | 4 | Investing.com | ||
| 24.08. | AEON Biopharma Inc: AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer | 456 | GlobeNewswire (Europe) | - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory... ► Artikel lesen | |
| 19.08. | AEON Biopharma Inc: AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX | 490 | GlobeNewswire (Europe) | - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed... ► Artikel lesen | |
| 17.08. | H.C. Wainwright senkt Kursziel für Aeon Biopharma Aktie wegen Verwässerung | 1 | Investing.com Deutsch | ||
| 17.08. | H.C. Wainwright cuts Aeon Biopharma stock price target on dilution | 2 | Investing.com | ||
| 13.08. | AEON Biopharma Q2 Non-GAAP EPS of -$0.02 | 1 | Seeking Alpha | ||
| 12.08. | AEON Biopharma Inc: AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 227 | GlobeNewswire (Europe) | - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program... ► Artikel lesen | |
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | AEON Biopharma regains NYSE American listing compliance after $13.6M offering | 1 | Seeking Alpha | ||
| 03.08. | AEON Biopharma Inc: AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | 153 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX... ► Artikel lesen | |
| 23.07. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | AEON Biopharma prices $13.75M offering with milestone warrants | 1 | Seeking Alpha | ||
| 14.07. | AEON Biopharma Inc: AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | 240 | GlobeNewswire (Europe) | IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)... ► Artikel lesen | |
| 09.07. | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.07. | AEON Biopharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,120 | +6,85 % | Biofrontera AG: FDA-Erfolg - diese Frage bleibt offen | ||
| TEMPUS AI | 63,60 | +0,39 % | Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? | ||
| DEFENCE THERAPEUTICS | 0,236 | -7,81 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| ABIVAX | 79,00 | +2,86 % | Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization | ||
| TRAWS PHARMA | 0,440 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,650 | +8,55 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 2,725 | +0,18 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 0,975 | +5,41 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| NEOVACS | 0,107 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 0,790 | +0,52 % | Alaunos Therapeutics, Inc. - 8-K, Current Report | ||
| ALTERITY THERAPEUTICS | 0,210 | -3,67 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders | ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,695 | -10,90 % | H.C. Wainwright reiterates Marker Therapeutics stock rating at buy | ||
| AINOS | 1,220 | +0,83 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,054 | 0,00 % | XFRA 6LJ: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMATINA.BIOPHA. O.N.... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,475 | +1,72 % | Enveric receives U.S. patent allowance for psychiatric compounds |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,002 (-0,74 %) liegt der Kurs bei 0,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.